Aberrant p53 alters DNA damage checkpoints in response to cisplatin: Downregulation of CDK expression and activity

International Journal of Cancer

Volumn 112, Issue 5, 2004, Pages 760-770

  Wrighton, Katharine H ^a,b   Prêle, Cecilia M ^a,c   Sunters, Andrew ^a,d   Yeudall, W Andrew ^a,e,f  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d HAMMERSMITH HOSPITAL   (United Kingdom)

^e VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^f Philips Institute of Oral and Craniofacial Molecular Biology   (United States)

Author keywords

Apoptosis; Cell cycle; Cisplatin; Cyclin; Kinase

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; CISPLATIN; COMPLEMENTARY DNA; CYCLIN A; CYCLIN A ASSOCIATED KINASE; CYCLIN B1; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 2; HISTIDINE; LEUCINE; PHOSPHOTRANSFERASE; PROTEIN BAX; PROTEIN KINASE; PROTEIN P53; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CELL STRAIN 3T3; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA DAMAGE; DOWN REGULATION; DRUG SENSITIVITY; ENZYME ACTIVITY; ENZYME ASSAY; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; MITOSIS INHIBITION; MOUSE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; WILD TYPE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CELL CYCLE; CISPLATIN; CYCLIN-DEPENDENT KINASES; DNA DAMAGE; DNA REPAIR; DNA, COMPLEMENTARY; DOWN-REGULATION; FIBROBLASTS; FLOW CYTOMETRY; GENES, CDC; HUMANS; IN SITU NICK-END LABELING; MICE; POINT MUTATION; TRANSPLANTATION, HETEROLOGOUS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 7244221424     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20446     Document Type: Article

References (64)

1. Strasser A, Harris AW, Jacks T, Cory S. DNA damage can induce apoptosis in proliferating lymphoid cells via p53-independent mechanisms inhibitable by Bcl-2. Cell 1994;79:329-39.
2. Lane DP. Cancer. p53, guardian of the genome. Nature 1992;358: 15-6.
3. Hermeking H, Eick D. Mediation of c-Myc-induced apoptosis by p53. Science 1994;265:2091-3.
4. 1-phase progression. Genes Dev 1999;13:1501-12.
5. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell 1993;75:817-25.
6. 2/M transition by p53. Oncogene 2001;20:1803-15.
7. Kastan MB, Zhan Q, el-Deiry WS, Carrier F, Jacks T, Walsh WV, Plunkett BS, Vogelstein B, Fornace AJ Jr. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 1992;71:587-97.
8. 2/M cell cycle checkpoint. Proc Natl Acad Sci U S A 1999;96:3706-11.
9. 2/M progression. Mol Cell 1997;1:3-11.
10. 2 checkpoint control: regulation of 14-3-3 protein binding by phosphorylation of Cdc25C on serine-216. Science 1997; 277:1501-5.
11. 2 checkpoint through cyclin B1. Proc Natl Acad Sci U S A 1999; 96:2147-52.
12. Krause K, Wasner M, Reinhard W, Haugwitz U, Dohna CL, Mossner J, Engeland K. The tumour suppressor protein p53 can repress transcription of cyclin B. Nucleic Acids Res 2000;28:4410-8.
13. Zhou J, Ahn J, Wilson SH, Prives C. A role for p53 in base excision repair. Embo J 2001;20:914-23.
14. Seo YR, Fishel ML, Amundson S, Kelley MR, Smith ML. Implication of p53 in base excision DNA repair: in vivo evidence. Oncogene 2002;21:731-7.
15. Hwang BJ, Ford JM, Hanawalt PC, Chu G. Expression of the p48 xeroderma pigmentosum gene is p53-dependent and is involved in global genomic repair. Proc Natl Acad Sci U S A 1999;96:424-8.
16. Cheo DL, Ruven HJ, Meira LB, Hammer RE, Burns DK, Tappe NJ, van Zeeland AA, Mullenders LH, Friedberg EC. Characterization of defective nucleotide excision repair in XPC mutant mice. Mutat Res 1997;374:1-9.
17. Smith ML, Ford JM, Hollander MC, Bortnick RA, Amundson SA, Seo YR, Deng CX, Hanawalt PC, Fornace AJ Jr. p53-mediated DNA repair responses to UV radiation: studies of mouse cells lacking p53, p21, and/or gadd45 genes. Mol Cell Biol 2000;20:3705-14.
18. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995;80:293-9.
19. Oda E, Ohki R, Murasawa H, Nemoto J, Shibue T, Yamashita T, et al. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science 2000;288:1053-8.
20. Oda K, Arakawa H, Tanaka T, Matsuda K, Tanikawa C, Mori T, Nishimori H, Tamai K, Tokino T, Nakamura Y, Taya Y. p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. Cell 2000;102:849-62.
21. Wu GS, Burns TF, McDonald ER, 3rd, Jiang W, Meng R, Krantz ID, Kao G, Gan DD, Zhou JY, Muschel R, Hamilton SR, Spinner NB, et al. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat Genet 1997;17:141-3.
22. Muller M, Wilder S, Bannasch D, Israeli D, Lehlbach K, Li-Weber M, et al. p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J Exp Med 1998;188:2033-45.
23. Kartalou M, Essigmann JM. Mechanisms of resistance to cisplatin. Mutat Res 2001;478:23-43.
24. Gonzalez VM, Fuertes MA, Alonso C, Perez JM. Is cisplatin-induced cell death always produced by apoptosis? Mol Pharmacol 2001;59: 657-63.
25. 2 phase and cell death induced by cisplatin. J Natl Cancer Inst 1990;82:749-55.
26. Chu G. Cellular responses to cisplatin. The roles of DNA-binding proteins and DNA repair. J Biol Chem 1994;269:787-90.
27. Ju JF, Banerjee D, Lenz HJ, Danenberg KD, Schmittgen TC, Spears CP, Schonthal AH, Manno DJ, Hochhauser D, Bertino JR, Danenberg PV. Restoration of wild-type p53 activity in p53-null HL-60 cells confers multidrug sensitivity. Clin Cancer Res 1998;4:1315-22.
28. Perego P, Giarola M, Righetti SC, Supino R, Caserini C, Delia D, Pierotti MA, Miyashita T, Reed JC, Zunino F. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res 1996;56:556-62.
29. Zamble DB, Jacks T, Lippard SJ. p53-Dependent and -independent responses to cisplatin in mouse testicular teratocarcinoma cells. Proc Natl Acad Sci U S A 1998;95:6163-8.
30. Gong JG, Costanzo A, Yang HQ, Melino G, Kaelin WG, Jr., Levrero M, Wang JY. The tyrosine kinase c-Ab1 regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature 1999;399:806-9.
31. Patel V, Ensley JF, Gutkind JS, Yeudall WA. Induction of apoptosis in head-and-neck squamous carcinoma cells by gamma-irradiation and bleomycin is p53-independent. Int J Cancer 2000;88:737-43.
32. Yeudall WA, Jakus J, Ensley JF, Robbins KC. Functional characterization of p53 molecules expressed in human squamous cell carcinomas of the head and neck. Mol Carcinog 1997;18:89-96.
33. Cardinali M, Kratochvil FJ, Ensley JF, Robbins KC, Yeudall WA. Functional characterization in vivo of mutant p53 molecules derived from squamous cell carcinomas of the head and neck. Mol Carcinog 1997;18:78-88.
34. Yeudall WA, Crawford RY, Ensley JF, Robbins KC. MTS1/CDK4I is altered in cell lines derived from primary and metastatic oral squamous cell carcinoma. Carcinogenesis 1994;15:2683-6.
35. Jakus J, Yeudall WA. Growth inhibitory concentrations of EGF induce p21 (WAF1/Cip1) and alter cell cycle control in squamous carcinoma cells. Oncogene 1996;12:2369-76.
36. Martinez LA, Yang J, Vazquez ES, Rodriguez-Vargas Mdel C, Olive M, Hsieh JT, Logothetis CJ, Navone NM. p21 modulates threshold of apoptosis induced by DNA-damage and growth factor withdrawal in prostate cancer cells. Carcinogenesis 2002;23:1289-96.
37. Detjen KM, Murphy D, Welzel M, Farwig K, Wiedenmann B, Rosewicz S. Downregulation of p21(waf/cip-1) mediates apoptosis of human hepatocellular carcinoma cells in response to interferon-gamma. Exp Cell Res 2003;282:78-89.
38. Gervais JLM, Seth P, Zhang H. Cleavage of CDK Inhibitor p21Cip1/ Waf1 by Caspases Is an Early Event during DNA Damage-induced Apoptosis. J Biol Chem 1998;273:19207-12.
39. Zhang Y, Fujita N, Tsuruo T. Caspase-mediated cleavage of p21Waf1/Cip1 converts cancer cells from growth arrest to undergoing apoptosis. Oncogene 1999;18:1131-8.
40. Seki K, Yoshikawa H, Shiiki K, Hamada Y, Akamatsu N, Tasaka K. Cisplatin (CDDP) specifically induces apoptosis via sequential activation of caspase-8, -3 and -6 in osteosarcoma. Cancer Chemother Pharmacol 2000;45:199-206.
41. Henkels KM, Turchi JJ. Cisplatin-induced apoptosis proceeds by caspase-3-dependent and -independent pathways in cisplatin-resistant and -sensitive human ovarian cancer cell lines. Cancer Res 1999;59: 3077-83.
42. Mochizuki T, Asai A, Saito N, Tanaka S, Katagiri H, Asano T, Nakane M, Tamura A, Kuchino Y, Kitanaka C, Kirino T. Akt Protein Kinase Inhibits Non-apoptotic Programmed Cell Death Induced by Ceramide. J. Biol. Chem. 2002;277:2790-97.
43. Haraguchi M, Torii S, Matsuzawa S-i, Xie Z, Kitada S, Krajewski S, Yoshida H, Mak TW, Reed JC. Apoptotic protease activating factor 1 (Apaf-1)-independent cell death suppression by Bcl-2. J. Exp. Med. 2000;191:1709-20.
44. Cummings BS, Schnellmann RG. Cisplatin-induced renal cell apoptosis: caspase 3-dependent and -independent pathways. J Pharmacol Exp Ther 2002;302:8-17.
45. Pirnia F, Schneider E, Betticher DC, Borner MM. Mitomycin C induces apoptosis and caspase-8 and -9 processing through a caspase-3 and Fas-independent pathway. Cell Death Diff 2002;9:905-14.
46. Fiers W, Beyaert R, Declercq W, Vandenabeele P. More than one way to die: apoptosis, necrosis and reactive oxygen damage. Oncogene 1999;18:7719-30.
47. Pestell KE, Hobbs SM, Titley JC, Kelland LR, Wallon MI. Effect of p53 Status on Sensitivity to Platinum Complexes in a Human Ovarian Cancer Cell Line. Mol Pharmacol 2000;57:503-11.
48. Kaneuchi M, Yamashita T, Shindoh M, Segawa K, Takahashi S, Furuta T, Fujimoto S, Fujinaga K. Induction of apoptosis by the p53-273L (Arg → Leu) mutant in HSC3 cells without transactivation of p21Waf1/Cip1/Sdi1 and bax. Mol Carcinog 1999;26:44-52.
49. Hawkins DS, Demers GW, Galloway DA. Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res 1996;56:892-8.
50. Yazlovitskaya EM, DeHaan RD, Persons DL. Prolonged wild-type p53 protein accumulation and cisplatin resistance. Biochem Biophys Res Commun 2001;283:732-7.
51. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependem apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993;74:957-67.
52. O'Connor PM, Jackman J, Bae I, Myers TG, Fan S, Mutoh M, Scudiero DA, Monks A, Sausville EA, Weinstein JN, Friend S, Fornace AJ Jr, et al. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res 1997;57:4285-300.
53. Lee K-H, Rudolph KL, Ju Y-J, Greenberg RA, Cannizzaro L, Chin L. Weiler SR, DePinho RA. Telomere dysfunction alters the chemotherapeutic profile of transformed cells. PNAS 2001;98:3381-86.
54. Hong M, Lai MD, Lin YS, Lai MZ. Antagonism of p53-dependent apoptosis by mitogen signals. Cancer Res 1999;59:2847-52.
55. Chang FL, Lai MD. Various forms of mutant p53 confer sensitivity to cisplatin and doxorubicin in bladder cancer cells. J Urol 2001;166: 304-10.
56. Gangopadhyay S, Jalali F, Reda D, Peacock J, Bristow RG, Benchimol S. Expression of Different Mutant p53 Transgenes in Neuroblastoma Cells Leads to Different Cellular Responses to Genotoxic Agents. Experimental Cell Research 2002;275:122-31.
57. Smith ML, Seo YR. p53 regulation of DNA excision repair pathways. Mutagenesis 2002;17:149-56.
58. Fan J, Bertino JR. Modulation of cisplatinum cytotoxicity by p53: effect of p53-mediated apoptosis and DNA repair. Mol Pharmacol 1999;56:966-72.
59. McKay BC, Becerril C, Ljungman M. P53 plays a protective role against UV- and cisplatin-induced apoptosis in transcription-coupled repair proficient fibroblasts. Oncogene 2001;20:6805-8.
60. D'Andrea AD. The Fanconi Anemia/BRCA signaling pathway: disruption in cisplatin-sensitive ovarian cancers. Cell Cycle 2003;2: 290-2.
61. Akkari YMN, Bateman RL, Reifsteck CA. D'Andrea AD, Olson SB, Grompe M. The 4N cell cycle delay in Fanconi anemia reflects growth arrest in late S phase. Molec Genet Metab 2001;74:403-12.
62. Falck J, Mailand N, Syljuasen RG, Bartek J, Lukas J. The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis. Nature 2001;410:842-7.
63. Wang JL, Wang X, Wang H, Iliakis G, Wang Y. CHK1-regulated S-phase checkpoint response reduces camptothecin cytotoxicity. Cell Cycle 2002;1:267-72.
64. Bradford CR, Zhu S, Ogawa H, Ogawa T, Ubell M, Narayan A, Johnson G, Wolf GT, Fisher SG, Carey TE. P53 mutation correlates with cisplatin sensitivity in head and neck squamous cell carcinoma lines. Head Neck 2003;25:654-61.